Wednesday, 28 September 2022

Bayers Eylea approved in Japan for child ratinopathy

Bayers Eylea approved in Japan for child ratinopathy
Bayers Eylea approved in Japan for child ratinopathy

Bayer announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Eylea (aflibercept) intravitreal injection 40 mg/mL for the treatment of preterm infants with retinopathy of prematurity (ROP).

Pradip Mahajan Wed, 09/28/2022 - 14:21

source https://www.pharmatutor.org/pharma-news/2022/bayers-eylea-approved-in-japan-for-child-ratinopathy

No comments:

Post a Comment

Pharmaceutical Industry and pharma / Life Sciences institute openings 2025

  Intas Pharma Walk in Drive for M.Pharm, B.Pharm | Multiple Posts M.Pharma / B.Pharma. Injectable/Parenteral/Sterile - Aseptic, Manufacturi...